With Libtayo now squarely in Regeneron’s hands, the drugmaker is eager to start cranking out combination therapies. But one near-term prospect is expected to suffer a...

Add two more failures to Merck & Co.’s recent string of Keytruda trial readouts. The once seemingly untouchable immuno-oncology agent appears to have hit a snag i...

It turns out that even more than the blinding pain, the nausea, the photosensitivity or crushing fatigue, the worst part of migraine is often the stigma attached to i...

More than a decade after Makena's FDA approval to prevent recurrent preterm birth and two years after the FDA recommended the drug be pulled from the market, Covis Ph...

Eli Lilly’s commitment to the immunology field has paid off with another important approval for JAK inhibitor Olumiant. And it's an industry first in alopecia areata....

Kyowa Kirin International (KKI) takes highlighting awareness of rare disease X-linked hypophosphatemia (XLH) literally with its immersive virtual exhibition, the “Shi...

Bad news for Aurobindo Pharma. Just two months after the generics maker closed up shop at its Aurolife Pharma unit in New Jersey, the company’s oral manufacturing fac...

In 2017 and 2020, Zejula snagged broad FDA labels for ovarian cancer patients who responded well to chemotherapy. But in prostate cancer, the PARP inhibitor appears t...